Therefore, we hypothesize that the two signaling pathways could be nonredundant and the co-inhibition of both pathways by combination of SHR6390 and pyrotinib may have synergistic anticancer activity on HER2+/HR+ breast cancer in vivo and in vitro. Here, ERBB2 is linked to breast cancer.